Explore 3 Stock Ideas & Industry Insights Download Free Report

Cellink AB (publ)

Company price
2.5425 USD 0.00(0%)
Last update at 2026-11-19T21:00:00Z
VOLUME
428
Market Cap
163.35M

Momentum Score

…

BICO Group AB (publ) provides hardware, laboratory automation, and software solutions in North America, Europe, Asia, and internationally. It operates through two segments: Life Science Solutions and Lab Automation. The Bioprinting segment offers 3D bioprinters and bioinks with a range of technologies for various applications, resolutions, and volume/speed requirements, as well as provides services focused on accelerating drug discovery and development. The Life Science Solutions segment supplies lab instrumentation, consumables and applications in cell culture, cell imaging, cell sorting, and sample preparation for different analytics, such as genomics, as well as offers instruments and solutions for the manufacturing of diagnostics, as well as consumables. The Lab Automation segment provides the proprietary and hardware-agnostic Green Button Go Suite software for connected workflows, as well as automation technology integration, and consulting and engineering services to design, build, and install automated laboratory systems. In addition, the company offers a range of services and consumables such as reagents, bioinks, plates, and tissue models. It serves pharma and biopharma, biotech, diagnostics, academia and research, and cosmetic industries. The company offers its products through sales organizations, as well as through distributor network. BICO Group AB (publ) was formerly known as Cellink AB (publ) and changed its name to BICO Group AB (publ) in August 2021. The company was incorporated in 2016 and is headquartered in Gothenburg, Sweden.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
2.40
Low
2.54
High
52 Week Price Range
1.78
Low
3.95
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

Cellink AB (publ) develops and sells instruments, consumables and software for 3D bioprinting and life‑science research, including bioinks and laboratory automation tools used in tissue engineering and drug discovery. Long‑term growth may be supported by rising adoption of 3D models, greater demand for predictive preclinical testing and recurring consumables revenue as researchers and pharma expand in vitro workflows. Investors may find the company attractive because it appears positioned in a specialized, expanding niche with product-driven recurring revenues.
Key risks include intense competition from larger life‑science equipment suppliers, sensitivity to academic and pharmaceutical R&D budgets and capital spending cycles, regulatory and validation hurdles for new applications, and execution risk from integrating acquisitions and scaling manufacturing.

Risk Score
Medium

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
2.54
Dividend Yield
-
Revenue TTM
1780.10M
Revenue Per Share
25.22
Gross Profit TTM
938.00M
Debt / Equity
0.86
ROE
-66.60%
Net Debt
222.24M
ROCE
-11.88%
Diluted EPS TTM
-2.43

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2022-08-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2022-08-31
Income before tax -1573.44M -70.60M -797.30M -753.10M -753.10M
Minority interest 4.20M 3.60M 1.10M 2.80M 2.80M
Net income -1086.17M -5.50M -1172.70M -832.90M -832.90M
Selling general administrative 303.50M 552.30M 986.20M 719.00M 719.00M
Selling and marketing expenses - 425.70M - - -
Gross profit 580.44M 1007.30M 993.30M 1830.60M 1830.60M
Reconciled depreciation 1271.60M 478.30M 1144.20M 940.60M 940.60M
Ebit -251.47M -284.00M - -618.30M -618.30M
Ebitda -34.81M -111.10M - 322.30M 322.30M
Depreciation and amortization 216.66M 172.90M - 940.60M 940.60M
Operating income -251.47M -289.10M -293.30M -996.90M -996.90M
Other operating expenses 1744.91M 2235.40M - 3257.30M 3257.30M
Interest expense 321.59M 97.60M 95.90M 98.20M 98.20M
Tax provision 6.40M 23.10M -8.60M 82.60M 82.60M
Interest income 37.60M 17.90M 18.30M 6.80M 6.80M
Net interest income -284.80M -74.00M -84.60M -108.10M -108.10M
Income tax expense 6.38M 23.10M - 82.60M 82.60M
Total revenue 1493.44M 1946.30M 2010.40M 2239.50M 2239.50M
Total operating expenses 831.91M 1296.40M 2303.80M 2848.40M 2848.40M
Cost of revenue 913.00M 939.00M 1017.20M 408.90M 408.90M
Total other income expense net -1321.98M 218.50M - 243.80M 243.80M
Net income from continuing ops -1583.70M -93.70M -788.70M -835.70M -835.70M
Net income applicable to common shares - - - -832.90M -832.90M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2022-08-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2022-08-31
Total assets 3687.33M 5483.20M 7897.80M 10196.80M 10196.80M
Intangible assets 519.50M 825.80M 1203.40M 1439.20M 1439.20M
Other current assets 96.96M 1459.95M - 0.10M 0.10M
Total liab 1943.01M 2475.60M 2989.90M 3264.60M 3264.60M
Total stockholder equity 1744.21M 2985.00M 4907.90M 6905.00M 6905.00M
Deferred long term liab - - - 462.10M 462.10M
Other current liab 178.85M 397.60M 78.90M 526.80M 709.20M
Common stock 1.80M 1.80M - 1.80M 1.80M
Capital stock 1.80M 1.80M 1.80M 1.80M 1.80M
Retained earnings -5936.87M -4861.80M -3094.40M -1106.60M -1106.60M
Other liab - - - 569.70M 569.70M
Good will 775.20M 2170.90M 3822.80M 5273.70M 5273.70M
Other assets - - - 604.00M 604.00M
Cash 1278.98M 598.00M 804.10M 925.20M 925.20M
Total current liabilities 1570.85M 570.80M 847.00M 939.50M 939.50M
Current deferred revenue 256.65M - - 594.80M 594.80M
Net debt 222.24M 1165.40M 618.20M 927.90M 927.90M
Short term debt 1065.92M 93.80M - 97.70M 97.70M
Short long term debt 1004.80M 6.70M 6.50M 8.00M 8.00M
Short long term debt total 1501.22M 1763.40M - 1853.10M 1853.10M
Other stockholder equity 7582.03M 7845.00M - 8009.80M 8009.80M
Property plant equipment - - - 901.60M 901.60M
Total current assets 2000.27M 1854.30M 2040.90M 2437.00M 2437.00M
Net tangible assets - - - 654.20M 654.20M
Net receivables 428.42M 50.18M 520.00M 1018.60M 1018.60M
Long term debt 0.20M 1337.10M 1415.80M 1384.90M 1384.90M
Inventory 195.91M 259.00M 405.20M 493.10M 493.10M
Accounts payable 69.43M 77.90M 170.20M 132.60M 132.60M
Accumulated other comprehensive income 97.26M - - - -
Non currrent assets other -2.60M 42.90M -0.10M 43.60M 43.60M
Non current assets total 1687.06M 3628.90M 5856.90M 7759.80M 7759.80M
Capital lease obligations 281.90M 419.60M 536.00M 460.20M 460.20M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2022-08-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2022-08-31
Investments 5.50M -4.10M 189.70M 212.90M 212.90M
Change to liabilities - - - 0.00M 0.00M
Total cashflows from investing activities 707.52M 128.00M - 212.90M 212.90M
Net borrowings -347.80M -105.60M -6.40M -78.10M -78.10M
Total cash from financing activities -453.96M -200.70M - 455.30M 455.30M
Change to operating activities - - - 85.40M 85.40M
Net income -1575.64M 8.10M -1983.20M -753.10M -753.10M
Change in cash 493.83M 85.30M 133.60M 444.00M 444.00M
Begin period cash flow 785.15M 861.00M 378.70M 481.20M 481.20M
End period cash flow 1278.98M 946.30M 680.50M 925.20M 925.20M
Total cash from operating activities 68.23M 158.40M -72.10M -269.40M -269.40M
Issuance of capital stock -0.20M 3.60M 493.00M 540.60M 540.60M
Depreciation 216.66M 478.30M 1929.30M 940.60M 940.60M
Other cashflows from investing activities - -43.20M - 705.20M -
Change to inventory 15.96M 92.20M -122.10M -162.10M -162.10M
Change to account receivables -1.90M 124.10M - -189.40M -189.40M
Other cashflows from financing activities -106.83M 3.28M - -81.00M -81.00M
Change to netincome - - - 508.60M 508.60M
Capital expenditures 13.27M 44.10M 454.10M 529.60M 529.60M
Change in working capital 112.52M 48.60M -110.60M -266.10M -266.10M
Stock based compensation 3.20M 2.10M -20.10M 39.00M 39.00M
Other non cash items 1314.69M -378.70M -113.50M -229.80M -229.80M
Free cash flow 54.96M 114.30M -643.00M -799.00M -799.00M

Peer Comparison*

Sector: Healthcare Industry: Medical Devices

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
CLLKF
Cellink AB (publ)
-
-%
2.54 - - 1.03 0.86 1.06 70.69
ABT
Abbott Laboratories
-0.20
0.19%
103.00 25.97 17.24 3.57 3.20 3.81 16.75
MDT
Medtronic PLC
-0.59
0.59%
100.02 26.60 15.87 3.35 2.08 3.90 14.12
SYK
Stryker Corporation
-
-%
310.00 29.23 16.86 4.18 4.51 4.63 17.16
SEMHF
Siemens Healthineers AG
-
-%
48.34 39.57 21.32 3.01 3.29 2.95 16.92

Profile*

Cellink AB (publ)

BICO Group AB (publ) provides hardware, laboratory automation, and software solutions in North America, Europe, Asia, and internationally. It operates through two segments: Life Science Solutions and Lab Automation. The Bioprinting segment offers 3D bioprinters and bioinks with a range of technologies for various applications, resolutions, and volume/speed requirements, as well as provides services focused on accelerating drug discovery and development. The Life Science Solutions segment supplies lab instrumentation, consumables and applications in cell culture, cell imaging, cell sorting, and sample preparation for different analytics, such as genomics, as well as offers instruments and solutions for the manufacturing of diagnostics, as well as consumables. The Lab Automation segment provides the proprietary and hardware-agnostic Green Button Go Suite software for connected workflows, as well as automation technology integration, and consulting and engineering services to design, build, and install automated laboratory systems. In addition, the company offers a range of services and consumables such as reagents, bioinks, plates, and tissue models. It serves pharma and biopharma, biotech, diagnostics, academia and research, and cosmetic industries. The company offers its products through sales organizations, as well as through distributor network. BICO Group AB (publ) was formerly known as Cellink AB (publ) and changed its name to BICO Group AB (publ) in August 2021. The company was incorporated in 2016 and is headquartered in Gothenburg, Sweden.

Grafiska vägen 2B, Gothenburg, Sweden, 412 63

46 7 35 46 57 77

570

Name Title Year Born
Mr. Erik Gatenholm Co-Founder, CEO, Pres & Director 1989
Dr. Hector Martinez Exec. VP, Co-Founder & CTO 1985
Mr. Mikael Engblom Interim Chief Financial Officer 1977
Ms. Asa Hillsten Sr. VP & Head of Investor Relations 1975
Lotta Bus SVP, Gen. Counsel & Sec. 1970
Ms. Karin Danielsson Global HR Director 1982
Ms. Erica Bell Sr. VP & Chief People Officer 1973
Mr. Artur Aira Sr. VP & Bus. Area Director - Bioprinting 1967
Ms. Itedale Namro Redwan Chief Scientific Officer - Bioprinting NA
Niclas Emanuelsson Head of Global Operations 1971

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Support

Hi! How can we help you today?

Loading…